|
|
|
|
|
|
|
14.08.26 - 08:21
|
Novo Nordisk gegen Eli Lilly: Darum spitzt sich der Streit jetzt zu (Der Aktionaer)
|
|
|
Die Aktie von Novo Nordisk war bis Mitte 2024 einer der großen Überflieger der Branche und in Europa. Seitdem ging es bei dem Wert aber steil bergab. Insbesondere die starke Konkurrenz aus den USA macht dem Unternehmen zu schaffen. Eli Lilly hat insbesondere im boomenden Markt für Abnehmmittel ordentlich Gas gegeben....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.08.26 - 13:33
|
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 (Business Wire)
|
|
|
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform
Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors
Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and CompanySEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B financing and the dosing of the first patient in the Phase 1 clinical study of IDP-001, the company's lead oncology program.
Proceeds from the financing will support Phase 1 clinical development and generation of early proof-of-concept data for IDP-001, as well as the adva...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
